Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM)

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 472-480

  Yoneda, Kazue ^a,b   Tanaka, Fumihiro ^a,b   Kondo, Nobuyuki ^a   Hashimoto, Masaki ^a   Takuwa, Teruhisa ^a   Matsumoto, Seiji ^a   Okumura, Yoshitomo ^a,c   Tsubota, Noriaki ^a   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Kuribayashi, Kozo ^d   Fukuoka, Kazuya ^a   Tabata, Chiharu ^a   Nakano, Takashi ^a   Hasegawa, Seiki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Itami City Hospital   (Japan)

^d ASAHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD; CELL COUNT; CHEMISTRY; FEMALE; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURAL NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; CELL ADHESION MOLECULES; CELL COUNT; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 84888812040     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3399-2     Document Type: Article

References (26)

1. Ismail-Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Siomn G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13:255–63.
2. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007;4:344–52.
3. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2009;35:479–95.
4. Stahel RA, Weder W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2000;21(Suppl5):v126–8.
5. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BAJM, Moons KGM. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325–33.
6. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant pleural mesothelioma. Cancer. 2007;109:1454–61.
7. Sculier JP, Berghmans T, Meert AP. Update in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2010;181:773–81.
8. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systemic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692–703.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
10. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888–96.
11. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.
12. Riethdort S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res. 2007;13:920–8.
13. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
14. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420–30.
15. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.
16. Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008;19:935–8.
17. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15:6980–6.
18. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.
19. Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch system. Cancer. 2007;109:1439–45.
20. Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancer. Ann Surg Oncol. 2008;15:3092–100.
21. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the international mesothelioma interest group. Lung Cancer. 1996;14;1–12.
22. Hanley JA, McNeil BJ. The meaning and the use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.
23. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–39.
24. Yoneda K, Tanaka F, Hashimoto M, et al. Circulating tumor cells (CTCs) and endothelial cells (CECs) in the diagnosis of malignant pleural mesothelioma (MPM): a single-institutional prospective study. American Society of Clinical Oncology 45th Annual Meeting (ASCO2009) 2009.6 Chicago.
25. Curren D, Sahmound T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–52.
26. Fennell DA, Parmer A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II studies. J Clin Oncol. 2005;23:184–9.